XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 Latest Research
 Infectious Diseases
 Respiratory Medicine
 Public Health
 Clinical Trials
 Medical News
 Awards & Prizes
 Special Topics
 Odd Medical News
 World News

Last Updated: Nov 17th, 2006 - 22:35:04

Nephrology Channel
subscribe to Nephrology newsletter

Latest Research : Nephrology

   DISCUSS   |   EMAIL   |   PRINT
Amitriptyline to be tested for painful bladder syndrome
Feb 18, 2005, 16:29, Reviewed by: Dr.

A new study will test an FDA-approved antidepressant for its potential to alleviate bladder pain for which there is no known cause and no effective therapy. Thousands, if not millions, of patients may benefit. The study is funded by the National Institutes of Health (NIH).

Ten medical centers in the United States and Canada are recruiting adults newly diagnosed with either painful bladder syndrome (PBS) or interstitial cystitis (IC) to learn if the oral drug amitriptyline (Elavil®) will reduce the pain and frequent urination that are hallmarks of the conditions. The centers make up the Interstitial Cystitis Clinical Research Network, sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at NIH.

PBS is defined by symptoms--frequent urination day and night and increasing pain as the bladder fills--according to the International Continence Society. The syndrome includes IC, which has been estimated to affect as many as 700,000 people, mostly women. Estimates for PBS vary widely, but as many as 10 million people may suffer from this condition.

The 270 participants will be randomly assigned to take up to 75 milligrams of amitriptyline or a placebo each day for 14 to 26 weeks. All will practice suppressing the urge to urinate for increasingly longer stretches until they can wait 3 or 4 hours before going to the bathroom. Participants will also regulate when and how much they drink and avoid bladder irritants such as alcohol, acidic foods and carbonated or caffeinated drinks. Staff and patients will find out who received the amitriptyline when the study is finished. Medications and tests are free to participants. Although amitriptyline is primarily used for depression, the way it works makes it useful for treating the pain of fibromyalgia, multiple sclerosis, and other chronic pain syndromes. Prior small studies in IC suggested the drug may be a wise choice for this syndrome as well, because it blocks nerve signals that trigger pain and may also decrease muscle spasms in the bladder, helping to cut both pain and frequent urination. An average of 75 milligrams of amitriptyline a day may begin relieving IC pain within a week. In contrast, doses in the range of 150 to 300 milligrams are generally used to treat depression.

"Like so many potential treatments tried before it, amitriptyline looks promising. And we are desperate to find a safe and effective treatment for patients. But until the drug is rigorously tested we won't know its true value in these syndromes," said Leroy M. Nyberg Jr., Ph.D., M.D., who oversees IC research sponsored by NIDDK. "And we'll never know if we are raising false hopes for patients, and unnecessarily spending health care dollars on prescriptions, if we don't do this study. It's critical to base our treatment decisions on evidence."

Eligibility criteria for the amitriptyline trial mark a major departure from two prior IC studies supported by NIDDK. The current trial is enlisting newly diagnosed adults and only those who have not yet received treatment.

Following up on earlier promising research supported by NIDDK, participants' urine will be checked for substances that may, ultimately, lead to a definitive test for diagnosing IC and for measuring the effectiveness of potential treatments.

- National Institute of Diabetes and Digestive and Kidney Diseases

Learn about IC

Subscribe to Nephrology Newsletter
E-mail Address:


ICCRN Clinical Centers and Investigators

Stanford University Medical Center
Christopher Payne, M.D.
Rodney Anderson, M.D.
Rajesh Shinghal, M.D.
Contact: Debra Clay, R.N. –
Research Coordinator
(650) 724-1753

CANADA, Kingston, Ontario
Queen's University
J. Curtis Nickel, M.D.
Laurel Emerson, R.N. CCRP
Contact: Joe Downey, M.Sc., CCRP –
Research Coordinator
(613) 533-2894
Sylvia Robb, R.N. - Research Associate
(613) 549-6666, Ext 4778

Loyola University Medical Center
Marypat Fitzgerald, M.D.
Linda Brubaker, M.D.
Contact: Judith Senka, R.N. –
Research Coordinator (708) 216-8495

IOWA, Iowa City
University of Iowa Hospitals and Clinic
Karl Kreder, M.D.
Michael O'Donnell, M.D.
Contact: Mary Eno, R.N. – Research Coordinator
(319) 384-9265
Kelley O'Berry –
Recruitment Coordinator
(319) 384-5064

MARYLAND, Baltimore
University of Maryland
Toby Chai, M.D.
Susan Keay, M.D.
Contact: Judith Murray, CCRC –
Research Coordinator
(410) 328-5784

Henry Ford Hospital
David Burks, M.D.
Contact: Jill Sullivan, R.N., B.S.N. –
Research Coordinator
(313) 916-3140
Michelle Peabody, R.N. –
Research Coordinator
(313) 916-8265

William Beaumont Hospital
Kenneth Peters, M.D.
Contact: Eleanor Anton, R.N. –
Research Coordinator
(248) 551-0885

NEW YORK, Rochester
University of Rochester Medical Center
Robert Mayer, M.D.
Edward M. Messing, M.D.
Contact: Elizabeth Smith, B.S. –
Research Coordinator
(585) 275-0989
Kay Rust, R.N., M.S.N., F.N.P – Research Coordinator
(585) 275-0133

PENNSYLVANIA, Philadelphia
University of Pennsylvania
Philip Hanno, M.D.
Diane Newman, R.N.C., M.S.N., CRNP
Contact: Lilliam Ribeiro, B.S. –
Research Coordinator
(215) 615-3780

University of Washington
Richard E. Berger, M.D.
Jane Miller, M.D.
Elizabeth A. Miller, M.D.
Contact: Sharon Downing, R.N. –
Research Coordinator
(206) 598-0850

Related Nephrology News

Kidney stones? Have some orange juice!!!
NOTCH2 gene mutations linked to Alagille syndrome
Fetal hydronephrosis mystery solved
Alport Syndrome: From Pathogenesis to a Potential Therapy
Meckel-Gruber syndrome gene identified- a help to understand polycystic kidney disease
Dialysis patients may be overmedicated
Mycophenolate mofetil may be more effective in inducing lupus nephritis remission
Dialysis patients often have close family members also on dialysis - Study
Prognosis Improving For Diabetics With End Stage Renal Disease
Osmolytes critical to survival of kidney cells

For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page


© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us